#LATEST NEWSResearchers have identified a new target for an aggressive type of blood cancer, offering a promising treatment option that could keep patients well for longer, with fewer side effects. Scientists at The Institute of Cancer Research, London, and The University of Edinburgh, discovered that blocking the TUT4/7 enzymes can significantly halt… Read More
#LATEST NEWSScientists have identified a brief window after brain tumour surgery during which a treatment for glioblastoma can cross the brain’s protective barrier and reach the cancer cells most likely to trigger tumour regrowth. The discovery could pave the way for more effective treatments for glioblastoma, the most… Read More
#LATEST NEWSInfinitopes has announced that the first patient has been dosed with ITOP1, the company’s lead investigational therapeutic cancer vaccine candidate. This marks the first clinical evaluation of Infinitopes’ Precision Immunomics platform, which combines large-scale immunopeptidomic antigen discovery with engineered viral vector technologies, to identify naturally presented tumour antigens capable of generating durable anti-tumour T-cell responses. Read More
#LATEST NEWSCancer Research UK and KisoJi Biotechnology have launched a new Phase I/IIa clinical trial for people with selected TROP2-expressing solid tumours. The study will evaluate the effectiveness and safety of KisoJi’s lead asset, KJ-103, a naked anti-TROP2 antibody. TROP2 is a transmembrane glycoprotein involved in… Read More
#LATEST NEWSAC Immune has received Fast Track designation and clearance of its Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) for its anti-alpha-synuclein (a-syn) active immunotherapy candidate, ACI-7104, for the treatment of early-stage Parkinson’s disease (PD). ACI-7104 is designed to induce… Read More
17 August 2026 · Diana Turner
17 August 2026 · Diana Turner
12 August 2026 · Diana Turner
18 August 2026 · Reece Armstrong
24 July 2026 · Reece Armstrong
23 July 2026 · Bruno Quinney
